Vermillion Granted US Patent Supporting Vasclir Diagnostic; Begins Intended-Use Study for Test

The patent covers "biomarker combinations that include B2-microglobulin for the diagnosis and management of peripheral artery disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay," the company said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.